This is a 24-week, randomized, double-blind, placebo-controlled, trial to evaluate the
safety, tolerability and efficacy of an orally administered growth hormone stimulating
drug, (code named MK-0677) in the treatment of female subjects with primary fibromyalgia.
The basis for this study is the observation that many fibromyalgia patients are growth
hormone deficient; an earlier study of injectable growth hormone had shown benefit in this
population of fibromyalgia patients.
This study examines whether MK-0677 treatment will improve symptoms of fibromyalgia (FM).
The rationale for this study is the observation that many fibromyalgia patients are growth
hormone deficient in terms of low levels of IGF-1, and that improving IGF-1 levels with
growth hormone injections has been shown to improve fibromyalgia symptoms.
MK-0677 is an orally administered growth hormone secretagogue manufactured by Merck & Co.,
Inc. that acts on the growth hormone secretagogue receptor in the anterior pituitary to
stimulate the release of growth hormone. This pathway represents an additional regulation
of growth hormone release from pituitary somatotrophs to that mediated by growth hormone
releasing hormone (stimulating) and somatostatin (inhibitory). Both stimulatory pathways
lead to a pulsatile release of growth hormone, with approximately 4 hour intervals between
peak levels. This growth hormone secretion leads to a rapid and robust up regulation of
IGF-1 levels by about 50 to 100% that can be maintained with chronic therapy at a dose of 25
The primary aims of this study are:
1. To evaluate the efficacy of MK-0677 25 mg in primary fibromyalgia subjects over a
24-week treatment period, as assessed by the FIQ.
2. To evaluate the safety and tolerability of MK-0677 25 mg in subjects with fibromyalgia.
The secondary aims of this study are to determine whether:
1. MK-0677 25 mg is superior to placebo in reducing muscle tenderness, as assessed by the
Fibromyalgia Myalgic Score (FMyS).
2. MK-0677 25 mg is superior to placebo in improving the subjects' global perception of
change in fibromyalgia symptoms, as assessed by the Subjects' Global Impression of
Change Questionnaire (PGIC).
3. MK-0677 25 mg is superior to placebo in improving the subjects' quality of life, as
assessed by the Quality of Life Questionnaire (QOL).
- Subjects will all be female primary fibromyalgia subjects who are 30 to 65 years of
age, inclusive, and have a low age adjusted serum IGF-1 level.
- All subjects will fulfill a diagnosis of fibromyalgia according to the classification
criteria of the American College of Rheumatology (ACR).
- All subjects will have an initial Fibromyalgia Impact Questionnaire (FIQ) score ≥ 40.
- If subject is of childbearing potential and sexually active, she agrees to use
effective barrier or appropriate oral contraception during the study. Subjects who
are taking oral contraceptives must have done so for at least 2 months prior to
entering the study.
- Subject is not pregnant and is not nursing.
- Patient has a normal screening breast exam. If screening breast exam is abnormal,
but not suggestive of breast cancer, the patient must have had a normal mammogram
within the last 6 months.
- Subject has a normal screening stool hemoccult. If the screening stool hemoccult is
abnormal, but likely due to hemorrhoids, the subject must have had a normal
sigmoidoscopy within the last 2 years.
- Subject is willing to discontinue using grapefruit juice for duration of study.
- Subject is willing to be followed by telephone contact for 3 months after she has
discontinued study and completed and returned the Fibromyalgia Impact Questionnaire,
Patient Global Change score, Quality of Life score, Brief Pain Inventory and Beck
- Subject has an-ongoing, unresolved disability litigation.
- Subject has diabetes or a significantly elevated random glucose at the Screening
- Subject has a current or past history of cardiovascular, pulmonary, neurological,
endocrine or renal disease that would preclude involvement in an exercise program
(specifically hypertension, a myocardial infarction within the last 6 months, chronic
obstructive pulmonary disease [COPD], asthma, untreated hypothyroidism, severe
depression with suicide risk, previous pituitary disease or surgery).
- Subject has a history of angina or congestive heart failure with symptoms that occur
- Subject has a history or current evidence of a psychotic disorder (e.g.
schizophrenia), bipolar disorder or major depression, or substance abuse by DSM-IV
criteria; severe depression, as evidenced by a Beck Depression score of ≥ 30.
- Subject has history of neurological disorder other than fibromyalgia (e.g. epilepsy,
stroke, neuropathy, neuropathic pain).
- Subject has ongoing symptoms of carpal tunnel syndrome.
- Subject has any other significant pain state, i.e. subject must have primary
- Subject has a history of hepatitis or liver disease that has been active within the
past 12 weeks.
- Subject has cancer or a history of cancer within the past 2 years, or a history of
cancer of more than 2 years ago and deemed to not be cured, or subject has ANY
history of breast cancer. (NOTE: Subjects with a history of basal cell or squamous
cell carcinoma of the skin treated more than 1 year ago and with no evidence of
recurrence may participate.)
- Subject has abnormal thyroid stimulating-hormone, or T4 concentrations.
- Subject has a planned elective surgery during the study period.
- Subject has a history of hypersensitivity or idiosyncratic reaction to more than 2
drug classes (by chemical classification).
- Subject has abnormal Screening visit laboratory values.
- Subject is using any of the following medications : heparin, ticlopidine, ginko (in
subjects taking warfarin), oral steroids (>/= 7 days per month), chronic use of
strong CYP3A4 inhibitors (HIV protease inhibitors, macrolide antibiotics and
nefazodone), chronic use of CYP3A4 inducers (carbamazepine, phenytoin, rifampin, and
St. John's Wort).
p. Subject has received an investigational drug or device within 30 days of study